1/2상모집 중
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
연구 개요
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
- 스폰서
- 리드: 로슈
- 적응증
- Non-Small Cell Lung Cancer
- 중재
- Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
- 목표 등록
- 320명
- 시작일
- 2023-06-20
- 완료(예정)
- 2032-01-29
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.